India-EU FTA Opens Door to Global Affordable Medicine Supply Chain

The concluded India-EU Free Trade Agreement is hailed as a landmark development for the pharmaceutical sector, promising to strengthen economic ties. It will facilitate near-zero duty on innovative EU products entering India, potentially lowering costs for patients. The agreement leverages India's strong track record in biosimilars, positioning the two regions as a combined global supplier of affordable, quality medicines. The deal, announced by top leaders, follows years of negotiation and reflects a shared vision for a modern economic partnership.

Key Points: India-EU FTA to Boost Affordable Global Medicine Supply

  • Landmark FTA covers 25% global GDP
  • Near-zero duty on EU innovative drugs to India
  • Strengthens India's biosimilar sector
  • Unlocks major trade & investment opportunities
3 min read

India, EU can be supplier of affordable medicines worldwide as India-EU FTA opens opportunities: Indian Pharmaceutical Alliance

Landmark trade deal aims to make India & EU a global supplier of affordable, quality medicines by reducing costs and strengthening pharma ties.

"India-EU can be a supplier of affordable medicines worldwide. - Sudarshan Jain"

New Delhi, January 29

The conclusion of the India-EU Free Trade Agreement has opened major opportunities for the two regions to emerge as a global supplier of affordable and quality medicines, according to the Indian Pharmaceutical Alliance.

Speaking on the significance of the agreement, Sudarshan Jain, General Secretary, Indian Pharmaceutical Alliance, said that the India-EU FTA is a landmark development, particularly for the pharmaceutical sector.

"The conclusion of India-EU FTA is a landmark moment as it covers 25 per cent of the global GDP and 23 per cent of the world population. This FTA is very important in the context of pharmaceuticals. It will further strengthen the relationship between India and the EU," he said.

Jain highlighted that the agreement would facilitate near-zero duty on the supply of innovative products from the European Union to India, which would help bring down costs for patients.

"There will be near-zero duty on the supply of the EU innovative products to India, which means innovative products will be available at lower cost," he added.

Emphasising India's strengths, Jain said that the country has a strong track record in the biosimilar segment.

"India has a strong record in biosimilars; overall, India-EU can be a supplier of affordable medicines worldwide," he said.

The India-EU FTA was jointly announced on Tuesday by Prime Minister Narendra Modi, European Commission President Ursula von der Leyen, and European Council President Antonio Costa at the 16th India-EU Summit, held during the visit of European leaders to India.

The documents related to the conclusion of the FTA were exchanged between EU Trade Commissioner Maros Sefcovic and Union Commerce Minister Piyush Goyal.

The announcement marks a historic milestone in India-EU economic relations and trade engagement with key global partners.

The FTA comes after intense negotiations following the re-launch of talks in 2022 and represents the culmination of years of sustained dialogue and cooperation between India and the EU.

The agreement reflects the political will and shared vision of both sides to deliver a balanced, modern, and rules-based economic and trade partnership.

The European Union is one of India's largest trading partners, with bilateral trade in goods and services witnessing steady growth over the years.

In 2024-25, India's bilateral trade in goods with the EU stood at Rs 11.5 lakh crore (USD 136.54 billion), with exports valued at Rs 6.4 lakh crore (USD 75.85 billion) and imports at Rs 5.1 lakh crore (USD 60.68 billion). India-EU trade in services reached Rs 7.2 lakh crore (USD 83.10 billion) in 2024.

The integration of these two large, diverse, and complementary economies is expected to create unprecedented trade and investment opportunities, including in the pharmaceutical sector.

- ANI

Share this article:

Reader Comments

R
Rohit P
Good step, but I hope the "near-zero duty" on EU products doesn't hurt our domestic manufacturers in the long run. We must ensure a level playing field. The focus should be on collaboration, not just opening our markets.
A
Arjun K
As someone whose family relies on regular medication, lower costs for innovative drugs would be a blessing. Hope the benefits reach the common man quickly and aren't just on paper. The biosimilar angle is particularly strong for India.
S
Sarah B
Interesting development from a global health perspective. Combining India's manufacturing scale and cost efficiency with EU innovation could really help address medicine accessibility issues worldwide. A powerful alliance.
V
Vikram M
The trade numbers are impressive! Rs 11.5 lakh crore with the EU shows how crucial this relationship is. This FTA should create many jobs in pharma and related sectors. A timely boost for the economy.
K
Karthik V
Hope the agreement includes strong IP protections that encourage our own R&D and innovation, not just manufacturing. We need to move up the value chain. Still, a landmark moment for sure.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50